Evidence accumulated to date suggests that extracellular group II phospholipase A2 (PLA2-II) is involved in the pathogenesis of inflammatory disease. During screening for PLA2 inhibitors, we found a novel PLA2inhibitor named thielocin B3 in the culture broth of an ascomycetes. Thielocin B3 strongly inhibited human PLA2-II (IC50 = 0.076 fiM) in a reversible and noncompetitive manner (Ki= 0.098 [M), whereas it inhibited human group I PLA2 only weakly (IC50 = 18 jum). It also quenched the tryptophan fluorescence ofNaja mocambique venom PLA2; almost 1 00%quenching being attained at a thielocin B3/enzyme molar ratio of 1.0. Its inhibitory activity toward humanPLA2-II and Naja mocambique PLA2was markedly decreased by methylation of its two carboxyl groups, while the quenching observed for Naja mocambiquePLA2was not altered. These results suggest that the two carboxyl groups do not participate in the binding of thielocin B3 to the enzyme, but play a crucial role in the PLA2 inhibition. Furthermore, in the rat carrageenan-induced pleurisy model, thielocin B3 significantly reduced both exudate volume and PLA2activity in the exudate when coinjected with carrageenan.
Evidence accumulated to date suggests that extracellular group II phospholipase A2 (PLA2-II) is involved in the pathogenesis of inflammatory disease. During screening for PLA2 inhibitors, we found a novel PLA2inhibitor named thielocin B3 in the culture broth of an ascomycetes. Thielocin B3 strongly inhibited human PLA2-II (IC50 = 0.076 fiM) in a reversible and noncompetitive manner (Ki= 0.098 [M) , whereas it inhibited human group I PLA2 only weakly (IC50 = 18 jum). It also quenched the tryptophan fluorescence ofNaja mocambique venom PLA2; almost 1 00%quenching being attained at a thielocin B3/enzyme molar ratio of 1.0. Its inhibitory activity toward humanPLA2-II and Naja mocambique PLA2was markedly decreased by methylation of its two carboxyl groups, while the quenching observed for Naja mocambiquePLA2was not altered. These results suggest that the two carboxyl groups do not participate in the binding of thielocin B3 to the enzyme, but play a crucial role in the PLA2 inhibition. Furthermore, in the rat carrageenan-induced pleurisy model, thielocin B3 significantly reduced both exudate volume and PLA2activity in the exudate when coinjected with carrageenan.
Phospholipase A2 (PLA2) forms a diverse family of enzymes that catalyze the hydrolysis of sn-2 fatty acyl ester bond of glycerophospholipids1) and exists in both extracellular and intracellular forms2). Much of the work on PLA2to date has focused on extracellular PLA2, because of its relative abundance in venoms and pancreatic juice3). Extracellular PLA2 can be classified into two types, group I (PLA2-I) and group II (PLA2-II), based on their primary structures40. Mammalian PLA2-I is abundantly present in the pancreatic digestive secretion5). On the other hand, mammalianPLA2-IIs are found in inflammatory regions, such as casein-induced peritoneal fluid in rats6), carrageenan-induced pleural exudate in rats7) and synovial fluid of patients with rheumatoid arthritis8). In addition, some inflammatory cytokines and lipopolysaccharide dramatically increased PLA2-II secretion in several tissues of rat through enhancement of gene transcription9 '10) .
These findings strongly implicate the importance of mammalian PLA2-II in promoting inflammatory processes. In fact, some studies have shown the pro-inflammatory activities of PLA2-IIll~13).
Recently, we isolated thielocin Alp, sl novel PLA2-II specific inhibitor, from the fermentation broth of Thielavia terricola RF-14314). It inhibited rat PLA2-II very strongly with an IC50 of 0.0033 /zm, but its inhibitory activity toward human PLA2-II was rather weak with an IC50 of 12^m15). In further screening, we isolated several analogues of thielocin AIf} from the same fermentation broth. Amongthem, thielocin B3 (Fig. 1) showed the strongest inhibitory activity toward human PLA2-II. The present study investigates the mechanism of thielocin B3 inhibition of human PLA2-II and the anti-inflammatory effect of thielocin B3 in rat carrageenan-induced pleurisy.
Materials and Methods

Materials
Thielocin Al/? and B3 were prepared as previously reported140. /7-Bromophenacyl bromide (p-BPB), 1-a-phosphatidylethanolamine (from egg yolk) and Naja mocambique mocambique PLA2 (pi 9.6) were purchased from Sigma (St. Louis, MO). L-3-Phosphatidylethanolamine, l-palmitoyl-2-[l-14C]linoleoyl (2.18 GBq/mmol) was purchased from Amersham Corp. HumanPLA2-I was purified from human pancreatic juice16). HumanPLA2-II was isolated from rheumatoid arthritic synovial fluid17). Rat PLA2-I was isolated from rat pancreas homogenate18). Rat PLA2-II was purified from rat platelets19). Naja mocambique mocambique PLA2 (pi 9.6) purchased from Sigma was further purified as described previously20).
Each Assay of PLA2 Activity PLA2activity was measured as described previously22). The substrate was prepared by diluting
phosphatidylethanolamine with L-a-phosphatidylethanolamine to the specific activity of 2,000 dpm/nmol. The reaction was started by addition of the enzyme. The amount of PLA2s was adjusted to linear kinetics for quantitation, i.e., less than 20%hydrolysis of the substrate. Thielocin B3 and Al/? were added to the assay tubes as a DMSOsolution (2% of the final volume), using a DMSO-enzymecontrol. Control experiments showed that DMSOat this concentration had no effect on enzymatic activities. Inhibition is expressed as the percent of enzyme control. IC5 0 values were determined graphically from plots of percent inhibition versus log concentration of inhibitors.
Fluorescence Measurements
The tryptophan fluorescence was measured in a Hitachi F-3000 fluorescence spectrophotometer. The sample in a total volume of 2.0ml contained 14nmol of Naja mocambique mocambique PLA2, 100mM Tris-HCl buffer (pH 7.4), 3 mMCaCl2 and the indicated concentrations of thielocin B3 was excited at 280 nmand emission was measured at 344nm.
Carrageenan-induced
Pleurisy in Rats and PLA2 Activity in Pleural Exudate. Male 8-to 10-week-old Sprague-Dawley rats (weighing 290~370 g) were slightly anesthetized with ether and injected with 0.5 ml of 0.2% carrageenan, dissolved in sterile saline solution, into the right pleural cavity through a blunt-edged 25-gauge needle. Five hours after carrageenan injection, the animals were sacrificed by exsanguination under ether anesthesia. The pleural exudate was harvested after opening the chest, and its volume was measured. The exudate containing blood was removed. The cavity was then washed with 1 ml of sterile saline. This wash was combined with the exudate to measure PLA2activity. The combined exudate was centrifuged at 2,000 x a for 15 minutes at 4°C immediately after collection to remove cells, and the superaatants were stored at -20°C until analysis. To assay PLA2activity in the pleural exudate, [3H]oleic acid-labeled Escherichia coli was used as substrate7).
Results
Inhibition of Human Extracellular
PLA2s by Thielocin B3 Thielocin B3 inhibited human PLA2-II very strongly in a dose-dependent manner with an IC50 of 0.076^m ( Fig. 2A) , whereas the inhibition by thielocin Al/? was 160 times weaker (IC50 of 12jjm) than that caused by thielocin B3. (Fig. 2B ). On the other hand, thielocin B3 and thielocin Aljft showed weak inhibitory activity against human PLA2-I with IC5Os of 18 /im and 140 fiM, respectively. Thus, thielocin B3 inhibition of human PLA2-II was 240 times stronger than that of human PLA2-I. In addition, the group II PLA2specific inhibitory activity of thielocin B3 was also conserved in rat extracellular PLA2s (for rat PLA2-I; IC5O=2.8 /zm, for rat PLA2-II; IC50 =0.012fiM). The inhibition of human PLA2s by thielocin B3 and thielocin Al/? was independent of Ca2 + and substrate concentration (data not shown). Furthermore, double reciprocal plot showed that thielocin B3 (Fig. 3A) and thielocin Al/? (Fig. 3B ) behaved kinetically as noncompetitive inhibitors for human PLA2-II with mean Ki of 0.098 and 12/lim, respectively. Thus, thielocin B3 showed 120 times higher affinity for human PLA2-II than thielocin Al/?.
Reversibility of Thielocin B3 Inhibition against HumanPLA2-II The reversible nature of thielocin B3 was confirmed by the dilution method of Lister et al. (Table  1 )23). After human PLA2-II was preincubated with thielocin B3 (37°C, 20 minutes) at 0.3 fiM, a concentration high enough to sufficiently reduce the enzymatic activity, a portion was removed and diluted 30-fold to 0.01 fiM with the assay mixture. Slight inhibition was observed, indicating reversible inhibition. Had the inhibition been irreversible, the rate would have been inhibited at least 89%, corresponding to an inhibitor concentration of 0.3 /^m. A similar result was observed when thielocin B3 was used at a concentration of The activities of the enzyme control (i.e. 100%) were from 4,000 to 5,900 nmol/minute/mg protein of human PLA2-I (o) and from 6, 100 to 8,200 nmol/minute/mg protein of human PLA2-II (à"). Inhibition is expressed as the percent ofenzyme control. Data points are the meansof three independent experiments, each performed in duplicate and corrected for no enzymatic hydrolysis (0.5% or less in all experiments). The SDvalue was 8%or less than the mean for each data point. showed similar inhibitory activity before and after dilution, indicating irreversible inhibition. Effect of Thielocin B3 on the Fluorescence Emission of Snake VenomPLA2 Direct interaction of thielocin B3 with snake venom PLA2(Naja mocambique) was examined by monitoring the tryptophan fluorescence of the enzymein the presence and absence of thielocin B3. Thielocin B3 quenched the relative fluorescence of 7.2/jm snake venom PLA2 at 344nm in a dosedependent manner (Fig. 4) . Approximately 100% of the fluorescence was quenched whenthe molar ratio of thielocin B3/enzyme was 1.0. To explore in more detail the inhibitory mechanismof thielocin B3 on PLA2?we examined the effect ofthielocin B3 methyl ester derivatives (see Fig. 1 ) on human PLA2-II. Twothielocin B3 monomethyl esters (b, c) and thielocin B3 dimethyl ester (d) showed inhibitory activity against human PLA2-II. However, the dose required for 50% inhibition increased on methylation; 0.20^m and 0.28/jm for thielocin B3 monomethyl esters (b and c), and 51 fM for thielocin B3 dimethyl ester (d). Thus, thielocin B3 showed a marked decrease (ca. 690 times) of its inhibitory activity against human PLA2-II on dimethylation. Similar results were obtained with Naja mocambiquevenomPLA2 (Table 2 ). On the other hand, quenching of relative fluorescent intensity of Naja mocambiquevenom PLA2by thielocin B3 was not markedly altered on methylation ( Table 2) .
Effect of Thielocin B3 on Exudate Volume and PLA2 Activity in Rat Carrageenan-Induced Pleurisy Recently, we have reported that PLA2-II activity in the exudate of pleural cavity was increased up to 24 hours after the intrapleural injection of carrageenan. In this model, thielocin Al/? correspondingly reduced both exudate volume and PLA2-II activity in the exudate in a dose-dependent manner when coinjection with carrageenan7). Thielocin B3 had the maximal inhibitory activity among the members against humanPLA2-II, and this led us to examine the effect of thielocin B3 on the volume of pleural exudate in rat carrageenan-induced pleurisy (Table 3) . At 5 hours after the injection of carrageenan, the exudate volume in the pleural cavity was dose-dependently decreased by thielocin B3 in a significant manner to 58 ± 3% (p<0.01) at 3 mg/kg, 80 ±4% (p<0.05) at 1 mg/kg. In addition, thielocin B3 significantly reduced the PLA2-II activity in the pleural exudate dose-respondingly to 12 + 9% at 3 mg/kg and 34+ 3% at l mg/kg. For reducing the exudate volume, both indomethacin, a cyclooxygenase inhibitor, and dexamethasone, a steroidal antiinflammatory drug, were more potent than thielocin B3. However, neither indomethacin nor dexamethasone administration resulted in significant reduction of the PLA2-II activity in the pleural exudate.
Discussion
These results demonstrated that thielocin B3, a novel PLA2 inhibitor isolated from fungi, inhibits both human PLA2-I and PLA2-II in a dose-dependent manner. In addition, the inhibitory activity of thielocin B3 is rather specific against human PLA2-II (Fig. 2) . Recently, human PLA2-II enriched in rheumatoid synovial fluid was purified from human platelets, and its gene was cloned and overexpressed24>25). Cloning and sequencing showed that the primary structure of human PLA2-II has about 35% homology with that of human pancreatic PLA2, which belongs to group I PLA2. However, the sequence of humanPLA2-II preserves the core of residues found to be invariant or highly conserved among extracellular PLA2s26). Furthermore, the X-ray crystal structures of human PLA2-II in the presence and absence of a transition state analogue, L-l -0-octyl-2-heptylphosphonyl-sn-glycero-3-phosphoethanolamine, have been reported27'28*. Scott et at. reported that the backbone conformation of the homologous core in the inhibited form of human PLA2-II is virtually superimposable on that found in the crystal structures of the pancreatic PLA2. On the contrary, the conformation of the homologous core in the uninhibited crystal form of human PLA2-II differs slightly from that described for other enzymes. The main contributor to this change is the amino-terminal helix, which provides side chains to the substrate-binding site and forms a substantial portion of the inter facial recognition surface28). Whether thielocin B3interacts with this site remains to be clarified, weare now conducting further studies to determine the structure of the complex between humanPLA2-II and thielocin B3.
In a recent paper15), we reported the inhibitory mechanism of rat PLA2-II by thielocin Al/?. It exhibits extremely strong inhibitory activity with an IC50 of 0.0033 /iM. However, against human PLA2-II, it shows rather weak activity with an IC50 of 12^M. It is noteworthy that thielocin B3 exhibits strong inhibitory activity against human PLA2-II (IC50 = 0.076 fiM). Furthermore, the double reciprocal plot shows that both thielocin B3 and thielocin Alj8 behave kinetically as noncompetitive inhibitors for human PLA2-II with Ki of 0.098 /iM and 12/xm, respectively (Fig. 3) . Therefore, thielocin B3 has 120 times higher affinity for human PLA2-II than thielocin Al/?. In addition, the ability of thielocin B3 to reversibly inhibit human PLA2-II was confirmed using the dilution method according to Lister et al.23) (Table 1) . These results distinguish thielocin B3 from agents such as manoalide and /?-BPB, which inhibit PLA2 by covalent modifications of lysine and histidine residues, respectively29'30*.
Direct, but non-covalent, interactions of inhibitory agents that modulate the structure of PLA2have been described in only rare instances. Several non-covalent PLA2inhibitors were examined for their direct interaction with the enzyme by the fluorescent method, and in this study, venomor pancreatic PLA2was used because of enzyme availability. Franson and Rosenthal3 1) reported that PGBx,oligomers of PGB1? directly interacted with Naja mocambique PLA2and 50%quenching was noted with a molar ratio of PGBx/enzymeof 1.5. In our experiments, approximately 100%of the fluorescence of Naja mocambique PLA2was quenched with the molar ratio of thielocin B3/enzyme at 1.0 (Fig. 4) . These observations indicated that inhibition of extracellular PLA2 by thielocin B3 may result from direct interaction with the enzyme.
Ballou and Cheung32) reported that unsaturated fatty acids inhibit human PLA2-II. Methylation of unsaturated fatty acids caused complete loss of inhibitory activity, while subsequent demethylation restored it, suggesting that a free carboxyl group is necessary. As thielocin B3 possesses two carboxyl groups at both ends, we examined the effect of two monomethylesters and a dimethyl ester of thielocin B3 on human PLA2-II ( Table 2 ). The inhibitory activity of thielocin B3 decreased with methylation and markedly decreased with dimethylation (690 times). On the other hand, quenching of the relative fluorescent intensity of Naja mocambique PLA2by thielocin B3 was not markedly altered by methylation. These results indicate that the two carboxyl groups of thielocin B3 may not participate in the interaction with the enzyme, but play a crucial role in the PLA2 inhibition.
Several investigators reported that inactivation of purified PLA2with /?-BPB before injection resulted in attenuation of the subsequent inflammatory reaction11}. We recently found that in the rat carrageenan-induced pleurisy model, thielocin A1/? correspondingly reduced both exudate volume and PLA2-II activity in the pleural exudate in a dose-dependent manner when coinjected with carrageenan. These results suggest that thielocin Al/? shows antiinflammatory activity due to inhibition of PLA2-II activity7). However, thielocin Al/? showed rather weak inhibitory activity against human PLA2-II (IC50 = 12fiM) as compared to rat PLA2-II (IC50 = 0.0033 /zm). On the other hand, thielocin B3 showed extremely strong inhibition activity against both human PLA2-II (IC50 = 0.074 jum) and rat PLA2-II (IC50 = 0.012^m). Interestingly, thielocin B3 administered intrapleurally at a dose of 3.0 mg/kg (Table 3 ) and intraperitoneally at a dose of 50mg/kg (unpublished data) decreased the exudate volume in the pleural cavity to 58 ±3% and 66 + 9%, respectively. Nakano and Arita reported33) that intravenously injection of endotoxin in rat increased both PLA2-II activity in the plasma and the levels of PLA2-II mRNAin the several tissues (aorta, spleen, lung and thymus) at 24 hours after endotoxin challenge. Moreover, accumulation ofPLA2-II mRNA in the tissues of endotoxin-treated rats was suppressed by dexamethasone administration. Hence, it may be possible that PLA2-II activity in that pleural exudate is reduced by administration of dexamethasone. Nevertheless, dexamethasone did not significantly decrease the PLA2-II activity in the pleural exudate, in spite of it remarkably reduced the exudate volume in the pleural cavity at 5 hours after the injection of carrageenan (Table 3) . Therefore, it may take longer period (over 5 hours) to reduce the PLA2-II activity in pleural exudate by dexamethasone administration in the rat carrageenan-induced pleurisy model. In conclusion, thielocin B3 showed the specific inhibitory activity against human PLA2-II and it also showed reduction of exudate volume in the rat carrageenan-induced pleurisy model. Therefore, further studies are now in progress to investigate the antiinflammatory activity of thielocin B3 and the involvement of PLA2-II in the pathogenesis of rat carrageenan-induced pleurisy.
